VRTX EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
VRTX's ev/ebitda is right around its 10-year median of 26.7.
EV/EBITDA History
VRTX EV/EBITDA by year
Yearly range of VRTX’s ev/ebitda from 2017 to 2026. Over the full period it ranged from 12.7 to 2,114.5, averaging 137.2.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 19.5 | 22.6 | 26.2 | 23.4 |
| 2025 | 19.9 | 92.5 | 270.2 | 23.8 |
| 2024 | 18.8 | 133.8 | 272.8 | 210.5 |
| 2023 | 14.5 | 17.7 | 21.4 | 21.2 |
| 2022 | 15.2 | 18.0 | 22.5 | 15.7 |
| 2021 | 12.7 | 15.9 | 18.5 | 17.3 |
| 2020 | 16.3 | 29.8 | 40.1 | 17.4 |
| 2019 | 35.2 | 54.4 | 68.7 | 35.2 |
| 2018 | 47.4 | 320.3 | 706.7 | 58.0 |
| 2017 | 74.2 | 621.5 | 2,114.5 | 2,035.6 |
Get notified when VRTX EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is VRTX EV/EBITDA High or Low Right Now?
Vertex Pharmaceuticals Incorporated's EV/EBITDA is currently 23.4, which is around average relative to its 10-year historical range. The 10-year median EV/EBITDA for VRTX is approximately 26.7. See all VRTX valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.